KPV
Also known as: Lys-Pro-Val, Alpha-MSH fragment
Buy in shop
KPV from $52/kit
3 verified vendors, ≥99% purity, COAs included.
Key Facts: KPV
- Category
- Immune
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Research ongoing
- Administration
- Subcutaneous injection or oral (capsules)
- Typical Dose
- 200-500 mcg daily
- Frequency
- 1-2x daily
- Duration
- 4-8 weeks typical
Mechanism of Action
KPV retains the anti-inflammatory properties of α-MSH without melanocortin receptor activation. It inhibits inflammatory pathways including NF-κB, reduces pro-inflammatory cytokines, and has antimicrobial properties.
Research Summary
Studies show effectiveness in inflammatory bowel disease models. Research demonstrates wound healing acceleration and antimicrobial activity. Being investigated for gut health and inflammatory conditions.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
200-500 mcg daily
100-1000 mcg daily
1-2x daily
Anti-inflammatory tripeptide. Used for gut inflammation and skin conditions. Can be taken orally or injected.
Research Dosingⓘ
Scientific studies
Doses from research protocols
Doses from Studies
200-500 mcg daily
Oral or subcutaneous
Duration
4-8 weeks typical
Administration
Subcutaneous injection or oral (capsules)
Timing & Administration
Best Time to Take
Morning or as directed
Once daily
Food Recommendation
With or without food
Why This Timing?
KPV is an anti-inflammatory peptide. Morning use for daytime inflammation management.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally very well-tolerated
- ●Injection site reactions
- ●Mild flu-like symptoms (transient)
- ●Mild GI effects
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Does NOT cause immunosuppression
- ●Contraindicated with cancer history
References
- https://pubmed.ncbi.nlm.nih.gov/18092346/
- https://pubmed.ncbi.nlm.nih.gov/18061177/
- https://pubmed.ncbi.nlm.nih.gov/10670585/
Research This Peptide Further
Buy in shop
KPV from $52/kit
3 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does KPV do?
A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
How does KPV work?
KPV retains the anti-inflammatory properties of α-MSH without melanocortin receptor activation. It inhibits inflammatory pathways including NF-κB, reduces pro-inflammatory cytokines, and has antimicrobial properties.
Is KPV FDA approved?
No, KPV is not currently FDA approved. Current status: Preclinical - Research ongoing
What are the side effects of KPV?
Reported side effects include: Generally very well-tolerated, Injection site reactions, Mild flu-like symptoms (transient), Mild GI effects, May trigger histamine release - use caution with MCAS or histamine sensitivity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of KPV?
Community-reported common dose: 200-500 mcg daily (1-2x daily). Range: 100-1000 mcg daily. Administration: Subcutaneous injection or oral (capsules). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with KPV or used in similar applications.
LL-37
Clinical TrialsA naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
ImmuneThymosin Alpha-1
Clinical TrialsA naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
ImmuneVIP
Clinical TrialsA naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
ImmuneThymogen
Clinical TrialsA synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
ImmunePNC27
PreclinicalA chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
ImmuneEnfuvirtide
FDAA peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.
ImmuneWant updates on KPV research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.